Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TNX 1700

Next Previous
Drug Profile

TNX 1700

Alternative Names: mTNX-1700; Recombinant Trefoil Family Factor 2; rTFF2; TNX-1700; Trefoil Family Factor 2 - Tonix Pharmaceuticals

Latest Information Update: 08 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University
  • Developer Columbia University; Tonix Pharmaceuticals Holding Corp
  • Class Anti-inflammatories; Antineoplastics; Biological factors; Recombinant fusion proteins
  • Mechanism of Action Trefoil factor-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Gastric cancer
  • No development reported Pancreatic cancer

Most Recent Events

  • 02 Jul 2025 Pharmacodynamics data from a preclinical trial in Gastric cancer released by Tonix Pharmaceuticals
  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Gastric cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Gastric cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top